Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial (2015)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.2337/dc14-1850
- Subjects: DIABTES MELLITUS (COMPLICAÇÕES); FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; INIBIDORES DE ENZIMAS; NEOPLASIAS (ETIOLOGIA)
- Language: Inglês
- Imprenta:
- Publisher place: Alexandria
- Date published: 2015
- Source:
- Título do periódico: Diabetes Care
- ISSN: 0149-5992
- Volume/Número/Paginação/Ano: v. 38, n. 4, p. 696-705, 2015
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
UDELL, Jacob A.; BHATT, Deepak L.; BRAUNWALD, Eugene; et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, Alexandria, v. 38, n. 4, p. 696-705, 2015. Disponível em: < http://care.diabetesjournals.org/content/38/4/696.full.pdf+html?sid=33cbf4f4-f641-4cad-8354-7afb474786de > DOI: 10.2337/dc14-1850. -
APA
Udell, J. A., Bhatt, D. L., Braunwald, E., Cavender, M. A., Mosenzon, O., Steg, G., et al. (2015). Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care, 38( 4), 696-705. doi:10.2337/dc14-1850 -
NLM
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.Available from: http://care.diabetesjournals.org/content/38/4/696.full.pdf+html?sid=33cbf4f4-f641-4cad-8354-7afb474786de -
Vancouver
Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg G, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im KA, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial [Internet]. Diabetes Care. 2015 ; 38( 4): 696-705.Available from: http://care.diabetesjournals.org/content/38/4/696.full.pdf+html?sid=33cbf4f4-f641-4cad-8354-7afb474786de - Anticoagulação e antiagregação plaquetária nas síndromes isquêmicas miocárdicas instáveis [Carta]
- Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study
- Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
- High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2°P - TIMI 50 Trial
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
- Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study
- Aplicação de hipotermia terapêutica em paciente com coronariopatia aguda
- Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
- I Diretriz da Sociedade Brasileira de Cardiologia sobre processos e competências para a formação em cardiologia no Brasil: resumo executivo
- Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
Informações sobre o DOI: 10.2337/dc14-1850 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
